226 related articles for article (PubMed ID: 21735230)
1. Comparative analysis of phase I and II enzyme activities in 5 hepatic cell lines identifies Huh-7 and HCC-T cells with the highest potential to study drug metabolism.
Lin J; Schyschka L; Mühl-Benninghaus R; Neumann J; Hao L; Nussler N; Dooley S; Liu L; Stöckle U; Nussler AK; Ehnert S
Arch Toxicol; 2012 Jan; 86(1):87-95. PubMed ID: 21735230
[TBL] [Abstract][Full Text] [Related]
2. The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics.
Guillouzo A; Corlu A; Aninat C; Glaise D; Morel F; Guguen-Guillouzo C
Chem Biol Interact; 2007 May; 168(1):66-73. PubMed ID: 17241619
[TBL] [Abstract][Full Text] [Related]
3. Influence of culture time on the expression of drug-metabolizing enzymes in primary human hepatocytes and hepatoma cell line HepG2.
Wilkening S; Bader A
J Biochem Mol Toxicol; 2003; 17(4):207-13. PubMed ID: 12898644
[TBL] [Abstract][Full Text] [Related]
4. Blood monocyte-derived neohepatocytes as in vitro test system for drug metabolism.
Ehnert S; Nussler AK; Lehmann A; Dooley S
Drug Metab Dispos; 2008 Sep; 36(9):1922-9. PubMed ID: 18559486
[TBL] [Abstract][Full Text] [Related]
5. Validation of in vitro cell models used in drug metabolism and transport studies; genotyping of cytochrome P450, phase II enzymes and drug transporter polymorphisms in the human hepatoma (HepG2), ovarian carcinoma (IGROV-1) and colon carcinoma (CaCo-2, LS180) cell lines.
Brandon EF; Bosch TM; Deenen MJ; Levink R; van der Wal E; van Meerveld JB; Bijl M; Beijnen JH; Schellens JH; Meijerman I
Toxicol Appl Pharmacol; 2006 Feb; 211(1):1-10. PubMed ID: 15975613
[TBL] [Abstract][Full Text] [Related]
6. HepaRG human hepatic cell line utility as a surrogate for primary human hepatocytes in drug metabolism assessment in vitro.
Lübberstedt M; Müller-Vieira U; Mayer M; Biemel KM; Knöspel F; Knobeloch D; Nüssler AK; Gerlach JC; Zeilinger K
J Pharmacol Toxicol Methods; 2011; 63(1):59-68. PubMed ID: 20460162
[TBL] [Abstract][Full Text] [Related]
7. Culture and Functional Characterization of Human Hepatoma HepG2 Cells.
Donato MT; Tolosa L; Gómez-Lechón MJ
Methods Mol Biol; 2015; 1250():77-93. PubMed ID: 26272135
[TBL] [Abstract][Full Text] [Related]
8. Involvement of the multidrug resistance P-glycoprotein in acetaminophen-induced toxicity in hepatoma-derived HepG2 and Hep3B cells.
Manov I; Bashenko Y; Hirsh M; Iancu TC
Basic Clin Pharmacol Toxicol; 2006 Sep; 99(3):213-24. PubMed ID: 16930294
[TBL] [Abstract][Full Text] [Related]
9. Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells.
Aninat C; Piton A; Glaise D; Le Charpentier T; Langouët S; Morel F; Guguen-Guillouzo C; Guillouzo A
Drug Metab Dispos; 2006 Jan; 34(1):75-83. PubMed ID: 16204462
[TBL] [Abstract][Full Text] [Related]
10. Primary culture of rat hepatocytes in 96-well plates: effects of extracellular matrix configuration on cytochrome P450 enzyme activity and inducibility, and its application in in vitro cytotoxicity screening.
Mingoia RT; Nabb DL; Yang CH; Han X
Toxicol In Vitro; 2007 Feb; 21(1):165-73. PubMed ID: 17141466
[TBL] [Abstract][Full Text] [Related]
11. Comparison of primary human hepatocytes and hepatoma cell line Hepg2 with regard to their biotransformation properties.
Wilkening S; Stahl F; Bader A
Drug Metab Dispos; 2003 Aug; 31(8):1035-42. PubMed ID: 12867492
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic Modifications of the Liver Tumor Cell Line HepG2 Increase Their Drug Metabolic Capacity.
Ruoß M; Damm G; Vosough M; Ehret L; Grom-Baumgarten C; Petkov M; Naddalin S; Ladurner R; Seehofer D; Nussler A; Sajadian S
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30654452
[TBL] [Abstract][Full Text] [Related]
13. Rabbit cytochrome P450 4B1: A novel prodrug activating gene for pharmacogene therapy of hepatocellular carcinoma.
Mohr L; Rainov NG; Mohr UG; Wands JR
Cancer Gene Ther; 2000 Jul; 7(7):1008-14. PubMed ID: 10917203
[TBL] [Abstract][Full Text] [Related]
14. Size-dependent effects of nanoparticles on the activity of cytochrome P450 isoenzymes.
Fröhlich E; Kueznik T; Samberger C; Roblegg E; Wrighton C; Pieber TR
Toxicol Appl Pharmacol; 2010 Feb; 242(3):326-32. PubMed ID: 19909766
[TBL] [Abstract][Full Text] [Related]
15. Role of constitutively activated and insulin-like growth factor-stimulated ERK1/2 signaling in human hepatoma cell proliferation and apoptosis: evidence for heterogeneity of tumor cell lines.
Alexia C; Lasfer M; Groyer A
Ann N Y Acad Sci; 2004 Dec; 1030():219-29. PubMed ID: 15659801
[TBL] [Abstract][Full Text] [Related]
16. Cytochrome P450 enzyme levels in HepG2 cells and cryopreserved primary human hepatocytes and their induction in HepG2 cells.
Westerink WM; Schoonen WG
Toxicol In Vitro; 2007 Dec; 21(8):1581-91. PubMed ID: 17637504
[TBL] [Abstract][Full Text] [Related]
17. The use of human hepatocytes to investigate drug metabolism and CYP enzyme induction.
Klieber S; Torreilles F; Guillou F; Fabre G
Methods Mol Biol; 2010; 640():295-308. PubMed ID: 20645059
[TBL] [Abstract][Full Text] [Related]
18. Cytochrome P450 expression in human hepatocytes and hepatoma cell lines: molecular mechanisms that determine lower expression in cultured cells.
Rodríguez-Antona C; Donato MT; Boobis A; Edwards RJ; Watts PS; Castell JV; Gómez-Lechón MJ
Xenobiotica; 2002 Jun; 32(6):505-20. PubMed ID: 12160483
[TBL] [Abstract][Full Text] [Related]
19. HepG2 cells simultaneously expressing five P450 enzymes for the screening of hepatotoxicity: identification of bioactivable drugs and the potential mechanism of toxicity involved.
Tolosa L; Gómez-Lechón MJ; Pérez-Cataldo G; Castell JV; Donato MT
Arch Toxicol; 2013 Jun; 87(6):1115-27. PubMed ID: 23397584
[TBL] [Abstract][Full Text] [Related]
20. Darbepoetin inhibits proliferation of hepatic cancer cells in the presence of TGF-β.
Ehnert S; Freude T; Eicher C; Burkhardt B; Martínez Sánchez JJ; Neumann J; Mühl-Benninghaus R; Dooley S; Pscherer S; Nussler AK
Arch Toxicol; 2014 Jan; 88(1):89-96. PubMed ID: 23877120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
